Aclaris to price IPO of 5 million shares between $14.00 and $16.00

Bookrunners Jefferies, Citigroup and William Blair to assist with sale

By Devika Patel

Knoxville, Tenn., Sept. 25 – Aclaris Therapeutics, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe of 750,000 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The deal was announced on Aug. 17.

The shares will be sold at a price expected to fall between $14.00 and $16.00 per share.

Jefferies, Citigroup and William Blair are the bookrunners.

Proceeds will be used for clinical trials, research and development, working capital and other general corporate purposes.

The pharmaceutical company is based in Malvern, Pa. The company intends to list its common stock on the Nasdaq under the symbol “ACRS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.